The National Institute of Dental and Craniofacial Research (NIDCR) awarded Virtici LLC a $923,623 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program. The objective of this 24-month award, effective September 19, 2024, is to advance a first-in-class cyclic peptide (VTC-880) towards clinical development for the treatment and prevention of gingivitis and periodontitis caused by oral infection with Porphyromonas gingivalis. Key activities include: 1) manufacturing and establishing analytical assays for VTC-880, 2) determining optimal formulation and in vitro pharmacokinetics in human saliva, 3) establishing oral pharmacokinetics and effective dose in mice, 4) generating acute toxicology profiles in mice and a human saliva biofilm model, and 5) finalizing IND-enabling and clinical study plans to advance VTC-880 into clinical trials.
Generated 2/25/25, 5:12 AM